Chronic obstructive pulmonary disease exacerbations: Latest evidence and clinical implications

Therapeutic Advances in Chronic Disease

Volumn 5, Issue 5, 2014, Pages 212-227

  Qureshi, Hammad ^a   Sharafkhaneh, Amir ^a   Hanania, Nicola A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bronchodilators; Chronic bronchitis; Chronic obstructive pulmonary disease; Emphysema; Exacerbation; Prevention; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; BRONCHODILATING AGENT; CARDIOVASCULAR AGENT; CORTICOSTEROID; INFLUENZA VACCINE; METHYLXANTHINE; MUCOLYTIC AGENT; PHOSPHODIESTERASE IV INHIBITOR; PNEUMOCOCCUS VACCINE;

AGE; BACTERIUM; BREATHING EXERCISE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; FUNGUS; HUMAN; INFLAMMATION; INTERACTIVE VENTILATORY SUPPORT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OXYGEN THERAPY; POPULATION RISK; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING CESSATION; VIRUS;

EID: 84905972097     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622314532862     Document Type: Review

References (96)

1. Aaron S. Vandemheen K. Hebert P. Dales R. Stiell I. Ahuja J. (2003) Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Eng J Med 348: 2618–2625.
2. Albert R. Connett J. Bailey W. Casaburi R. Cooper J. Jr Criner G. (2011) Azithromycin for prevention of exacerbations of COPD. N Eng J Med 365: 689–698.
3. Albert R. Martin T. Lewis S. (1980) Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 92: 753–758.
4. Alfageme I. Vazquez R. Reyes N. Muñoz J. Fernández A. Hernández M. (2006) Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61: 189–195.
5. American Thoracic Society / European Respiratory Society (2010) Standards for the diagnosis and management of patients with COPD. Version 1.2. Available at: www.thoracic.org/go/copd (accessed 13 September 2010).
6. Anthonisen N. Connett J. Kiley J. Altose M. Bailey W. Buist A. (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA 272: 1497–1505.
7. Anzueto A. Ferguson G. Feldman G. (2009) Effect of fluticasone propionate / salmeterol (250 / 50) on COPD exacerbations and impact on patient outcomes. COPD 6: 320–329.
8. Anzueto A. Sethi S. Martinez F. (2007) Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4: 554–564.
9. Au D. Bryson C. Chien J. Udris E. Evans L. Bradley K. (2009) The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med 24: 457–463.
10. Barr R. Rowe R. Camargo C. (2003) Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomized trials. BMJ 327: 643.
11. Beghé B. Verduri A. Roca M. Fabbri L. (2013) Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 41 (4): 993–995.
12. Bourbeau J. Julien M. Maltais F. Rouleau M. Beaupré A. Bégin R. (2003) Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 163: 585-591.
13. Bourbeau J. Nault D. Dang-Tan T. (2004) Self-management and behavior modification in COPD. Patient Educ Couns 52: 271–277.
14. Brightling C. Monteiro W. Ward R. Parker D. Morgan M. Wardlaw A. et al (2000) Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356: 1480-1485.
15. British Thoracic Society (2006) Burden of Lung Disease Report, 2nd edn. Available at: www.britthoracic.org.uk/copd/pubs_frameset.html (accessed 2 May 2007).
16. Burge P. Calverley P. Jones P. Spencer S. Anderson J. Maslen T. (2000) Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297–1303.
17. Calverley P. Anderson J. Celli B. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775–789.
18. Calverley P. Rabe K. Goehring U. Kristiansen S. Fabbri L. Martinez F. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685–694.
19. Celli B. MacNee W. Agusti A. Anzueto A. Berg B. Buist A. et al. (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur Resp J 23: 932–946.
20. Christenhusz L. Prenger R. Pieterse M. Seydel E. van der Palen J. (2012) Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob Res 14: 657–663.
21. Clini E. Beghé B. Fabbri L. (2013) Chronic obstructive pulmonary disease is just one component of the complex multimorbidities in patients with COPD. Am J Respir Crit Care Med 187: 668–671.
22. Clini E. Crisafulli E. Radaeli A. Malerba M. (2013) COPD and the metabolic syndrome: an intriguing association. Intern Emerg Med 8: 283–289.
23. Collet J. Shapiro S. Ernst P. (1997) Effect of an immunostimulating agent on acute exacerbations and hospitalization in COPD patients. Am J Respir Crit Care Med 156: 1719–1724.
24. COMBIVENT Inhalation Solution Study Group (1997) Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 112: 1514–1521
25. Dal Negro R. Micheletto C. Tognella S. Visconti M. Turati C. (2008) Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation. Adv Ther 25: 1019–1030.
26. Decramer M. Rutten-van Mölken M. Dekhuijzen P. Troosters T. van Herwaarden C. et al. (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 365: 1552–1560.
27. Dobler C. Wong K. Marks G. (2009) Associations between statins and COPD: a systematic review. BMC Pulmon Med 9: 32.
28. Donaldson G. Seemungal T. Bhowmik A. Wedzicha J. (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847–852.
29. Donaldson G. Wilkinson T. Hurst J. Perera W. Wedzicha J. (2005) Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 446–452.
30. Dransfield M. Bourbeau J. Jones P. Hanania N. Mahler D. Vestbo J. (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Resp Med 234: 210–223.
31. Erelel M. Cuhadaroglu C. Ece T. Arseven O. (2002) The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 96: 515–518.
32. Esteban A. Frutos F. Tobin M. Alía I. Solsona J. Valverdu V. (1995) A comparison of four methods of weaning patients from mechanical ventilation. N Eng J of Med 332: 345–350.
33. Fan V. Gaziano J. Lew R. Bourbeau J. Adams S. Leatherman S. (2012) A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations a randomized, controlled trial. Ann Int Med 156: 673–683.
34. Ferrer M. Sellarés J. Valencia M. Carrillo A. Gonzalez G. Badia J. (2009) Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. Lancet 374: 1082–1088.
35. Gerrits C. Herings R. Leufkens H. Lammers J. (2003) N-acetylcysteine reduces the risk of re-hospitalization among patients with chronic obstructive pulmonary disease. Eur Respir J 21: 795–798.
36. Godtfredsen N. Lam T. Hansel T. Leon M. Gray N. Dresler C. (2008) COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Resp J 32: 844–853.
37. GOLD (2011) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available at: http://www.goldcopd.org.
38. GOLD (2013) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. February. Available at: http://www.goldcopd.org.
39. Granger R. Walters J. Poole P. (2006) Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4: CD001390.
40. Gravil J. Al-Rawas O. Cotton M. Flanigan U. Irwin A. Stevenson R. (1998) Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. Lancet 351: 1853–1855.
41. Griffiths T. Burr M. Campbell I. (2000) Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation. Lancet 355: 362–368.
42. Han M. Martinez F. (2011) Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proc ATS 8: 356–362.
43. Hurst J. Donaldson G. Quint J. Goldring J. Baghai-Ravary R. Wedzicha J. (2009) Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 179: 369–374.
44. Hurst J. Vestbo J. (2010) Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128–1138.
45. Johnson M. Rennard S. (2001) Alternative mechanisms for long-acting beta (2)-adrenergic agonists in COPD. Chest 120: 258–270.
46. Karpel J. Pesin J. Greenberg D. Gentry E. (1990) A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. CHEST J 98: 835–839.
47. Keatings V. Jatakanon A. Worsdell Y. (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155: 542–548.
48. Kim V. Han M. Vance G. Make B. Newell J. Hokanson J. et al. (2011) The chronic bronchitic phenotype of COPD: an analysis of the COPD Gene study. Chest 140: 626–633.
49. Kochanek K. Xu J. Murphy S. Miniño A. Kung H. (2011) Deaths: final data for 2009. Natl Vital Stat Rep 60: 3–11.
50. Lehouck A. Mathieu C. Carremans C. Baeke F. Verhaegen J. van Eldere J. et al. (2012) High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 156: 105–114.
51. Lopez A. Shibuya K. Rao C. Mathers C. Hansell A. Held L. et al. (2006) Chronic obstructive pulmonary disease: current burden and future projections. ERS J 27: 397–412.
52. Maggiore S. Richard J. Abroug F. Diehl J. Antonelli M. Sauder P. et al. (2010) A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med 38: 145–151.
53. Mahon J. Laupacis A. Hodder R. McKim D. Paterson N. Wood T. et al. (1999) Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 115: 38–48.
54. Malerba M. Radaeli A. Morjaria J. (2012) Therapeutic potential for novel ultra long-acting β-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 17: 496–504.
55. Malolepszy J. Boszormenyi N. Selroos O. (2001) Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. Eur Respir J 18: 928–934.
56. Maltais F. Ostinelli J. Bourbeau J. (2002) Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 165: 698–703.
57. McCrory D. Brown C. (2002) Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4: CD003900.
58. Miravitlles M. Guerrero T. Mayordomo C. Sánchez-Agudo L. Nicolau F. Segú J. (2000) Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 67: 495–501.
59. Moayyedi P. Congleton J. Page R. Pearson S. Muers M. (1995) Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 50: 834–837.
60. Murray P. Washington J. (1975) Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 50: 339–344.
61. Nichol K. Baken L. Nelson A. (1999) Relation between influenza vaccination and outpatient visits, hospitalization and mortality in elderly patients with chronic lung disease. Ann Intern Med 130: 397–403.
62. Niewoehner D. Erbland M. Deupree R. Collins D. Gross N. Light R. et al. (1999) Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Medi 340: 1941–1947.
63. Niewoehner D. Lokhnygina Y. Rice K. (2007) Risk indexes for exacerbations and hospitalizations due to COPD. Chest 131: 20–28.
64. Polosa R. Malerba M. Cacciola R. Morjaria J. Maugeri C. Prosperini G. et al. (2011) Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med 1–8: 567–674.
65. Price L. Lowe D. Hosker H. Anstey K. Pearson M. Roberts C. (2006) UK National COPD Audit 2003: impact of hospital resources and organization of care on patient outcome following admission for acute COPD exacerbation. Thorax 61: 837–842.
66. Puhan M. Scharplatz M. Troosters T. Steurer J. (2005) Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review. Respir Res 6: 54.
67. Ram F. Rodriguez-Roisin R. Granados-Navarrete A. Garcia-Aymerich J. Barnes N. (2006) Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev CD004403.
68. Rice K. (2010) Disease management program for COPD. AJRCCM 182: 890–896.
69. Rizkallah J. Man S. Sin D. (2009) Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 135: 786–793.
70. Roca M. Verduri A. Corbetta L. Clini E. Fabbri L. Beghé B. (2013) Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 43: 510–521.
71. Rutten F. Zuithoff N. Hak E. Grobbee D. Hoes A. (2010) {beta}-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 170: 880–887.
72. Saetta M. Di Stefano A. Maestrelli P. (1994) Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150: 1646–1652.
73. Sapey E. Stockley R. (2006) COPD exacerbations.2: Aetiology. Thorax 61: 250–258.
74. Seemungal T. Donaldson G. Bhowmik A. Jeffries D. Wedzicha J. (2000) Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161: 1608–1613.
75. Seemungal T. Donaldson G. Paul E. Bestall J. Jeffries D. Wedzicha J. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 151: 1418–1422.
76. Sethi S. (1999) Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 43(Suppl. A): 97–105.
77. Sethi S. Jones P. Theron M. Miravitlles M. Rubinstein E. Wedzicha J. et al. (2010) Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 11: 10.
78. Sethi S. Murphy T. (2008) Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359: 2355–2365.
79. Sharafkhaneh A. Mattewal A. (2010) Budesonide / formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis 5: 357–366.
80. Sharafkhaneh A. Southard J. Goldman M. Uryniak T. Martin U. (2012) Effect of budesonide / formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Resp Med 106: 257–268.
81. Short P. Lipworth S. Elder D. Schembri S. Lipworth B. (2011) Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 342: d2549.
82. Sin D. Lacy P. York E. (2004) Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 760–765.
83. Soler M. Mutterlein R. Cozma G. ; Swiss-German OM-85 Study Group (2007) Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 74: 26–32.
84. Soler-Cataluña J. Martínez-García M. Román Sánchez P. Salcedo E. Navarro M. et al. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925–931.
85. Sprenkle M. Niewoehner D. MacDonald R. Rutks I. Wilt T. (2005) Clinical efficacy of OM–85 BV in COPD and chronic bronchitis: a systematic review. COPD 2: 167–175.
86. Ställberg B. Selroos O. Vogelmeier C. Andersson E. Ekström T. Larsson K. (2009) Budesonide / formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res 10: 11.
87. Tashkin D. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S. et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543–1554.
88. Thompson W. Nielson C. Carvalho P. (1996) Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 154: 407–412.
89. Tse H. Raiteri L. Wong K. Yee K. Ng L. Wai K. (2013) High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 144: 106–118.
90. Turner M. Patel A. Ginsburg S. FitzGerald J. (1997) Bronchodilator delivery in acute airflow obstruction: a meta-analysis. Arch Int Med 157: 1736–1744.
91. Wang C. Wang S. Lai C. Lin L. Chou P. (2007) Impact of influenza vaccination on major cause-specific mortality. Vaccine 26: 1196–1203.
92. Wang J. Nie B. Xiong W. Xu Y. (2012) Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 37: 204–211.
93. Wongsurakiat P. Maranetra K. Wasi C. Kositanont U. Dejsomritrutai W. Charoenratanakul S. (2004) Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 25: 1971–1972.
94. Vestbo J. Lisa D. Scanlon P. Yates J. Agusti A. Bakke P. et al. (2011) Changes in forced expiratory volume in 1 second overtime in COPD. N Engl J Med 365: 1184–1192.
95. Vogelmeier C. Hederer B. Glaab T. Schmidt H. Rutten-van Mölken M. Beeh K. (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364: 1093–1103.
96. Zheng J. Kang J. Huang S. Chen P. Yao W. Yang L. et al. (2008) Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. The Lancet 371: 2013–2018.